Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Oncology · 03.08.2026 · 1-26
DOI: 10.1159/000553349 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 03.08.2026. Verfasst von Emi Tanaka und 58 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
Abstract (Originalsprache)
Aim
The lymphocyte-to-monocyte ratio (LMR) has emerged as a potential immune-related biomarker; however, its prognostic significance in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (Atezo/Bev) remains unclear. To investigate the prognostic significance of the LMR in patients with unresectable HCC treated with Atezo/Bev.
Methods
This multicentre study included 941 patients with unresectable HCC treated with Atezo/Bev therapy at 30 institutions in Japan. The optimal LMR cutoff value was determined using time-dependent receiver operating characteristic (ROC) analysis. Multivariate survival analyses were performed for progression-free survival (PFS) and overall survival (OS). The prognostic utility of the LMR was compared with that of the neutrophil-to-lymphocyte ratio (NLR) using integrated discrimination improvement and net reclassification improvement.
Results
Time-dependent ROC analysis identified an optimal LMR cutoff value of 3.6 based on median OS. The median PFS was 5.6 months in patients with an LMR < 3.6 and 8.9 months in those with an LMR ≥ 3.6 (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan.
- Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, Kobe, Japan.
- Department of Gastroenterology, Ehime Prefectural Central Hospital, Matsuyama, Japan.
- Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Japan.
- Department of Gastroenterology, Okayama City Hospital, Okayama, Japan.
- Department of Gastroenterology and Neurology, Kagawa University, Takamatsu, Japan.
Zitieren
APA
Tanaka, E., Tada, T., Hiraoka, A., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., Nishimura, T., Tsuji, K., Ishikawa, T., Tajiri, K., Tanaka, H., Toyoda, H., Ogawa, C., Hatanaka, T., Kakizaki, S., Kawata, K., …, & RELPEC Group (2026). Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Oncology, 1-26. https://doi.org/10.1159/000553349
Vancouver
Tanaka E, Tada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, et al. Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab. Oncology. 2026:1-26. doi:10.1159/000553349
BibTeX
@article{Tanaka2026,
author = {Tanaka, Emi and Tada, Toshifumi and Hiraoka, Atsushi and Hirooka, Masashi and Kariyama, Kazuya and Tani, Joji and Atsukawa, Masanori and Takaguchi, Koichi and Itobayashi, Ei and Nishimura, Takashi and Tsuji, Kunihiko and Ishikawa, Toru and Tajiri, Kazuto and Tanaka, Hironori and Toyoda, Hidenori and Ogawa, Chikara and Hatanaka, Takeshi and Kakizaki, Satoru and Kawata, Kazuhito and Naganuma, Atsushi and Kosaka, Hisashi and Kuroda, Hidekatsu and Yata, Yutaka and Nishikawa, Hiroki and Imai, Michitaka and Aoki, Tomoko and Ochi, Hironori and Tamai, Hideyuki and Komatsu, Shohei and Matsuura, Takanori and Ueda, Yoshihide and Matono, Tomomitsu and Kim, Soo Ki and Ohama, Hideko and Tada, Fujimasa and Nakamura, Shinichiro and Nakamura, Yoshiko and Yoshida, Osamu and Nouso, Kazuhiro and Morishita, Asahiro and Itokawa, Norio and Okubo, Tomomi and Arai, Taeang and Tsutsui, Akemi and Nagano, Takuya and Tanaka, Kazunari and Koshiyama, Yuichi and Kanayama, Yuki and Noritake, Hidenao and Enomoto, Hirayuki and Matsui, Kosuke and Kaibori, Masaki and Okamura, Jumpei and Fukumoto, Takumi and Hiasa, Yoichi and Kudo, Masatoshi and Kumada, Takashi and HCC 48 Group, HCC 48 Group and RELPEC Group, RELPEC Group},
title = {Usefulness of the Lymphocyte-to-Monocyte Ratio in Predicting Prognosis in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab},
journal = {Oncology},
year = {2026},
pages = {1--26},
doi = {10.1159/000553349}
}
EUVIMED